Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/234557
Authors: 
Nitzan, Jonathan
Bichler, Shimshon
Year of Publication: 
2021
Series/Report no.: 
Research Note
Abstract: 
A lot has been written on the imminent decline of pharmaceuticals: their falling production, reduced R&D, declining innovation, the opioid crisis, patent cliffs, biting competition from generic drugs, growing opposition to IPR. The list goes on. Judging by the yardsticks that matter the most, though – namely, the companies’ relative profit and relative capitalization – pharmaceuticals are doing just fine. In fact, based on these yardsticks, they remain the most powerful corporate sector of all.
Subjects: 
capitalization
finance
pharmaceutical
power
profit
JEL: 
P16
P26
URL of the first edition: 
Creative Commons License: 
https://creativecommons.org/licenses/by-nc-nd/4.0/
Document Type: 
Working Paper

Files in This Item:





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.